

UNIVERSAL DEFINITION MI HISTORIQUE




Figure 1. Changing criteria for the definition of myocardial infarction (MI). ACC = American College of Cardiology; AHA = American Heart Association; ESC = European Society of Cardiology; ISFC = International Society and Federation of Cardiology; NHLBI = National Heart, Lung, and Blood Institute; WHF = World Heart Foundation; WHO = World Health Organization.

ACUTE MYOCARDIAL INFARCTION(TYPE1 MI)

Acute myocardial infarction (type I MI)

Acute Myocardial injury

Acute myocardial ischaemia.

-**Injury**: Detection of a **rise and/or fall** of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least **one value above the 99th percentile upper reference limit (URL)** and with at least **one of the following**:

-**Ischemia.**

-Clinic

-ECG Changes ST-T LBBB Q-waves


-Imaging evidence

-**Identification of an intracoronary thrombus by angiography or autopsy.**

TYPE 1 MI

- **STEMI**
- ST-segment elevation Myocardial Infarction
- **N-STEMI**
- non ST-segment elevation Myocardial Infarction
- The case of **Unstable Angina**


STEMI



STEMI-LBBB



N-STEMI ECG




THE 99TH PERCENTILE UPPER REFERENCE LIMIT

The 99th percentile URL is designated as the decision level for the presence of myocardial injury and **must be determined for each specific assay** with quality control materials.

Clinicians should be aware that for all cTn assays, including hs-cTn assays, there is still **no expert opinion or consensus about specific criteria for how the 99th percentile URL should be defined....**

Myocardial Infarction Type 1



Plaque rupture/erosion with
occlusive thrombus



Plaque rupture/erosion with
non-occlusive thrombus


N-STEMI/UA INVASIVE STRATEGY

- Increased cardiac biomarkers (troponin, CK-MB)
- New ST segment depression
- Signs or symptoms of congestive heart failure (rales on examination, hypoxia with pulmonary edema on chest X-ray)
- Hemodynamic instability
- Sustained ventricular tachycardia or ventricular fibrillation
- Recent coronary intervention within 6 months
- Prior coronary artery bypass grafting
- High TIMI risk score
- Reduced left ventricular systolic function (EF < 40%)
- Recurrent angina at rest or with low level activity
- High-risk findings from non-invasive testing


MYOCARDIAL INJURY RELATED TO ACUTE MYOCARDIAL ISCHAEMIA BECAUSE OF OXYGEN SUPPLY/DEMAND IM BALANCE TYPE 2 MI

Reduced myocardial perfusion,

Increased myocardial oxygen demand,



^aIschaemic thresholds vary substantially in relation to the magnitude of the stressor and the extent of underlying cardiac disease.



Plaque rupture with thrombus



MI Type 1

Vasospasm or endothelial dysfunction



MI Type 2

Fixed atherosclerosis and supply-demand imbalance



MI Type 2

Supply-demand imbalance alone



MI Type 2

Figure 2 Differentiation between myocardial infarction (MI) types 1 and 2 according to the condition of the coronary arteries.

Type 1: Spontaneous myocardial infarction

Spontaneous myocardial infarction related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus in one or more of the coronary arteries leading to decreased myocardial blood flow or distal platelet emboli with ensuing myocyte necrosis. The patient may have underlying severe CAD but on occasion non-obstructive or no CAD.

Type 2: Myocardial infarction secondary to an ischaemic imbalance

In instances of myocardial injury with necrosis where a condition other than CAD contributes to an imbalance between myocardial oxygen supply and/or demand, e.g. coronary endothelial dysfunction, coronary artery spasm, coronary embolism, tachy-/brady-arrhythmias, anaemia, respiratory failure, hypotension, and hypertension with or without LVH.

Type 3: Myocardial infarction resulting in death when biomarker values are unavailable

Cardiac death with symptoms suggestive of myocardial ischaemia and presumed new ischaemic ECG changes or new LBBB, but death occurring before blood samples could be obtained, before cardiac biomarker could rise, or in rare cases cardiac biomarkers were not collected.

Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI)

Myocardial infarction associated with PCI is arbitrarily defined by elevation of cTn values $>5 \times 99^{\text{th}}$ percentile URL in patients with normal baseline values ($\leq 99^{\text{th}}$ percentile URL) or a rise of cTn values $>20\%$ if the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial ischaemia, or (ii) new ischaemic ECG changes or new LBBB, or (iii) angiographic loss of patency of a major coronary artery or a side branch or persistent slow- or no-flow or embolization, or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are required.

Type 4b: Myocardial infarction related to stent thrombosis

Myocardial infarction associated with stent thrombosis is detected by coronary angiography or autopsy in the setting of myocardial ischaemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99^{th} percentile URL.

Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG)

Myocardial infarction associated with CABG is arbitrarily defined by elevation of cardiac biomarker values $>10 \times 99^{\text{th}}$ percentile URL in patients with normal baseline cTn values ($\leq 99^{\text{th}}$ percentile URL). In addition, either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native coronary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

MYOCARDIAL INFARCTION WITH NON-OBSTRUCTIVE CORONARY ARTERIES (MINOCA)

It is increasingly recognized that a group of MI patients has no angiographic obstructive ($\geq 50\%$ diameter stenosis) CAD and the term **Myocardial infarction with non-obstructive coronary arteries (MINOCA)** has been coined for this entity.

The prevalence of MINOCA is estimated to be 6–8% among patients diagnosed with MI.

Atherosclerotic plaque disruption and coronary thrombosis may be a cause of MINOCA, i.e. type 1 MI. However, **coronary spasm and spontaneous coronary dissection** may be involved as well, i.e. type 2 MI.

MYOCARDIAL INJURY

Small amounts of myocardial injury with necrosis may be detected without Ischemia


[Ischémie — Wikipédia](#)

Une **ischémie** (prononcer /is.ke.mi/ ; du grec ancien ἴσχω, ískhō (« tenir ») et αἷμα, haîma (« sang ») est la diminution de l'apport sanguin artériel à un organe

CRITERIA FOR MYOCARDIAL INJURY

Detection of an elevated cTn value above the 99th percentile URL is defined as myocardial injury. The injury is called **acute if there is a rise and/or fall of cTn values**

MYOCARDIAL INJURY



Myocardial injury that may occur unrelated to acute myocardial ischaemia

Cardiac conditions

Heart failure

Myocarditis

Cardiomyopathy

Takotsubo syndrome

Coronary revascularization procedure

Non-coronary cardiac surgery

Transcatheter valve replacement

Ablation, defibrillator shocks

Cardiac contusion

Systemic conditions

Sepsis, infectious disease

Chronic kidney disease

Stroke, subarachnoid haemorrhage

Pulmonary embolism


Chemotherapeutic agents

Strenuous exercise



TROPONINE

- Troponin is a myofibrillar regulatory protein complex of exclusively muscular origin
- TnT fixes troponin-complex to tropomyosin
- TnI has Ca-binding site
- Cardiac specific isoforms of TnT and TnI



BIOMARKER DETECTION OF MYOCARDIAL INJURY


Cardiac troponin I (cTnI) and T (cTnT) are components of the contractile apparatus of myocardial cells and are expressed almost exclusively in the heart.

Increases in cTnI values have not been reported to occur following injury to non-cardiac tissues.


The situation is **more complex for cTnT**. Biochemical data indicate that injured skeletal muscle can manifest the ability to express proteins that are detected by the cTnT assay

cTnI and cTnT are the preferred biomarkers for the evaluation of myocardial injury, and when available, **hs-cTn assays are recommended for routine clinical use.**


TROPONIN: INFARCTION AND CHRONIC INJURY



HS-TROPONIN



TROPONINE EN CLINIQUE



CENTRAL ILLUSTRATION: Patient Assessment With Suspected ACS

	Likelihood of myocardial infarction (MI)				
	LOW				HIGH
I. Clinical setting Symptoms and vital signs					
II. Electrocardiogram (ECG)	Normal ECG	ST depression (mild)	ST depression	ST depression	ST elevation
III. Troponin level at 0h		-	-/+	+	++ ++++
IV. Troponin change (within 1, 2 or 3h)		-	-/+	+	++ If any of the above, consider direct rule-in
Triage decision	Rule-out MI		Observe		Rule-in MI
Differential diagnosis	Noncardiac		Unstable angina	Other cardiac	NSTEMI STEMI

Twerenbold, R. et al. J Am Coll Cardiol. 2017;70(8):996-1012.




RULE-IN/RULE-OUT



RULE-IN RULE OUT À UNE HEURE ROCHE ELECSYS

Algorithme à 1h⁶

Conformément aux directives européennes, seuls les tests de troponine cardiaque ultra-sensibles (voir définition ci-dessus) conviennent à l'application de l'algorithme à 1h. Ce protocole permet une exclusion sûre ainsi qu'une confirmation après seulement 1 heure. Ce nouvel algorithme garantit sécurité et gain de temps pour tous. L'algorithme se caractérise par une excellente validation et peut être appliqué en toute sécurité.^{8,11}



[Vue détaillée](#)

Les valeurs sont spécifiques à l'essai et données ici pour hs-TropT de Roche. L'algorithme 0/1h s'applique pour la douleur mammaire > 3h.

Test hs TropT pour la stratification du risque⁶

Outre le diagnostic d'infarctus aigu du myocarde, la hs-TropT convient aussi à titre de biomarqueur pour l'évaluation du risque face à des événements cardiaques à court et long terme. La pertinence d'un pronostic est encore meilleure si l'on associe les paramètres hs-TropT et NT-proBNP.

IT IS IMPORTANT TO HIGHLIGHT 5 ASPECTS WHEN APPLYING TROPONIN-BASED STRATEGIES IN CLINICAL PRACTICE

First, they *should be used only in conjunction with **full clinical assessment***, including a pre-test probability assessment

Second, these strategies should be considered **triage strategies rather than definite diagnostic strategies**

Third, **the percentage of patients eligible for rule-out or rule-in varies widely from $\approx 9.8\%$ to 77%** depending on the underlying algorithm, the cTn assay used, and the clinical setting, including the prevalence of MI .


Fourth, **these strategies should only be applied after the initial ECG has excluded ST-segment elevation myocardial infarction (STEMI)**

Fifth, **all triage strategies should be embedded in the local standard operating procedures of the ED**



**Takotsubo and Stroke Heart:
Two examples of Myocardial Injury**

Le **syndrome de *tako-tsubo*** (蛸壺), littéralement « piège à poulpe »), appelé également **syndrome des cœurs brisés** ou **ballonnisation apicale**





Japanese octopus pot

STRESS CARDIOMYOPATHY/TAKOTSUBO SYNDROME

An increasingly recognised acute **HF syndrome with myocardial injury** which mimics MI is known as stress cardiomyopathy (SCM) or Takotsubo syndrome (TTS)

SCM/TTS occurs in approximately **1–2% of patients presenting with suspected STEMI**, and when presentation is delayed it can also mimic non-STEMI.

The onset of SCM/TTS is frequently, but not always, triggered by **intense emotional or physical stresses such as bereavement**

Over 90% of patients reported in the largest cohorts are postmenopausal women, although younger women and men may also develop SCM/TTS.

Acute cardiovascular complications occur in approximately 50% of patients presenting with SCM/TTS, and the inpatient mortality is similar to STEMI (4–5%) due to cardiogenic shock, ventricular rupture or malignant arrhythmias.¹⁶⁰

SUSPICION OF TAKOTSUBO

The diagnosis of SCM/TTS should be suspected when the clinical manifestations and electrocardiographic abnormalities are out of proportion to the degree of elevation of cTn values and **when the distribution of the LV wall motion abnormalities do not correlate with a single coronary artery distribution.**

STROKE HEART

Acute cardiac troponin increases (with rising and/or falling patterns) in stroke patients might either be caused by a concomitant primary coronary event resulting in acute myocardial ischemia (type 1 MI) or **acute myocardial injury secondary to the stroke.**

Acute alterations in the autonomic control of the heart with exaggerated catecholamine release have been suggested as a possible noncoronary mechanism of acute cardiac injury in ischemic stroke

The INSULA is important for the central autonomic regulation and is frequently affected in anterior circulation stroke, and an association between Right insula cortex stroke and increased cardiac troponin has been shown .

CKD (CHRONIC KIDNEY DISEASE)

Thus, baseline elevation of cTn values is common, and because they reflect myocardial injury, such elevation is highly prognostic over time.

PROMISE

TROPONIN IN STABLE OUTPATIENTS

Background **Evaluation of stable symptomatic outpatients** with suspected coronary artery disease (CAD)
Objectives This study sought to evaluate the prognostic meaning of single-molecule counting high-sensitivity troponin I (hsTnI) (normal range <6 ng/l) among outpatients with stable chest symptoms and suspected CAD.

Results The study sample consisted of 4,021 participants; 98.6% had measurable hsTnI concentrations. The median hsTnI value was 1.6 ng/l. In upper hsTnI quartiles, patients had higher-risk clinical profiles. Higher hsTnI concentrations were associated with greater event probabilities for death, acute MI, or hospitalization for unstable angina.

Conclusions **In symptomatic outpatients with suspected CAD, higher concentrations of hsTnI within the normal range were associated with heightened near-term risk for death, acute MI, or hospitalization.**

CENTRAL ILLUSTRATION: Troponin and Risk of CVD Outcomes

Study Data


154,052 participants without CVD
recruited by 28 prospective studies

Cardiac Troponin Concentration

Detectable in 80% with high-sensitivity assays

Risk of a First-ever CVD Event

Relative risk comparing **top** vs. **bottom** third



CVD	+43%
Fatal CVD	+67%
CHD	+59%
Stroke	+35%

Willeit, P. et al. J Am Coll Cardiol. 2017;70(5):558-68.

When Troponin was a lousy essay, it was a great test. Now that it's a great assay it's a lousy test

Dr Bob Jesse +2017

